Company intelligence / Profile preview

GenePlus

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

GenePlus provides validated NGS-based oncology and pathogen testing assays, including large cancer gene panels, MRD monitoring, and personalized testing in clinical use. The company achieved international CLIA laboratory qualification in 2021, and partners for global distribution.

Therapeutic areas: OncologyInfectious Diseases
Modalities: DNA sequencingNext generation sequencing (NGS)
Industry: Molecular Diagnostics

Partnerships

Euroclone (precision oncology partnership, Europe)MGI Tech (NGS partnership)

Beyond the preview

Go deeper on GenePlus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GenePlus.

Explore the full profile